PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Egypt; Department of Pharmacology, Toxicology and Biochemistry, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.\', \'Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Egypt. Electronic address: rehab.shamma@pharma.cu.edu.eg.\', \'Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Egypt.\', \'Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Egypt.\', \'Department of Endemic Medicine and Hepatogastroenterology, Faculty of Medicine, Cairo University, Egypt.\', \'Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.\', \'Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt; Pharmaceutical Factory, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1567-5769(21)00640-810.1016/j.intimp.2021.108004
?:doi
?:hasPublicationType
?:journal
  • International immunopharmacology
is ?:pmid of
?:pmid
?:pmid
  • 34333358
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.051
?:rankingScore_hIndex
  • 94
is ?:relation_isRelatedTo_publication of
?:title
  • Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all